| Study Period | 2019 - 2032 |
| 2024 Market Size | USD 4.3 Billion |
| 2025 Market Size | USD 4.7 Billion |
| 2032 Forecast | USD 9.4 Billion |
| Growth Rate (CAGR) | 10.50% |
| Largest Region | North America |
| Fastest Growing Region | APAC |
| Nature of the Market | Consolidated |
| Largest Application Category | Oncology |
|
Explore the market potential with our data-driven report
The single-cell analysis market value stood at USD 4.3 billion in 2024, and it is expected to advance at a CAGR of 10.5% during 2025–2032, to reach USD 9.4 billion by 2032.
As per the WHO, new diagnoses of cancer around the globe are expected to increase to 35 million by 2050 from 20 million in 2022, reflective a massive rise of 77%. Moreover, single-cell analysis enables researchers to study the functions of cells in complex tissues. Researchers in the U.S. estimate that the majority of single cell isolating systems can analyze 800 cells at a time.
Among all types of cells, human cells are widely used for analysis, due to the rising prevalence of infectious diseases among older people, initiatives of governments for stem cell research, and the extensive use of human cells in research labs and academic institutes.
Various key players have announced the availability of new products, such as fixed RNA profiling and nuclei isolation kits, for single-cell analysis. For instance, two U.S.-based biotechnology companies recently collaborated to launch the first portable single-cell RNA sequencing solution, which aids in RNA sequencing library preparation for different kinds of cells. Moreover, many U.S.-based companies are investing for accelerating the launch of AI-based platforms for the development of medicine.
The majority of the products work on the principle of whole-genome next-generation sequencing technology, which is able to analyze heterogeneity among cells with high accuracy. Moreover, many of these tests have a chromium platform, for the analysis of fragile human tissue samples.
The consumables category held the larger share, around 65%, in 2024, and it will also grow faster during the forecast period. This is due to the increasing demand for isolation products, continuous purchase of reagents for research, and constant need for assay kits. An increase in the prevalence of target diseases and the continuous requirement for different products for exosome analysis and isolation of the DNA and RNA are also propelling the growth of this category.
The technological advancements in software tools, high-throughput assays, microfluidics, gene sequencing, and single cell amplification products and the widening availability of these products to healthcare settings, diagnostic laboratories, and academic institutions contribute in driving the sales growth.
The demand for instruments is growing at a lucrative rate, as they possess technically advanced features and superior clinical accuracy. Among instruments, NGS systems dominate the sales, as a large number of cells can be analyzed in a short period using this technology.
These products are part of the research scope:
Oncology dominates the market, and it also has the highest CAGR, of 12%, because researchers believe that single-cell analysis is the most effective for the diagnosis of cancer.
The most-widely occurring cancers are breast, lung, colon, rectum, and prostate cancers. According to the American Cancer Society, after coronary illnesses, cancer continues to be the second-biggest reason of death in the U.S. In 2022, a total of 1.9 million cases of cancer and about 609,360 deaths are expected. Moreover, it is estimated that about 8 in 10 deaths from lung cancer result from smoking cigarettes and exposure to radon gas.
Further, according to the WHO, in low-and-middle-income countries, about 30% of the cancer cases are due to the human papillomavirus. Moreover, researchers in the U.S. estimate that about 1 in 8 U.S. women will develop breast cancer during their life. Moreover, as per government reports, it is estimated that about 10,470 children and 5,480 adolescents will be diagnosed with cancer each year.
It is necessary to detect cancer at an early stage, to reduce the number of deaths. An increase in the prevalence of this disease is, thus, driving the market for single-cell analysis.
We analyzed these applications:
Academic and research laboratories hold the largest share, of 45%, in 2024 due to the introduction of spatial genomics. Moreover, the development of new tools and technological advancements, such as the use of microfluidics, are driving the market for single-cell analysis. The growth is essentially because of a significant increase in the number of research and academic laboratories.
Biotechnology and biopharmaceutical companies are witnessing the fastest growth in the market, on account of the rising biologics R&D and increasing preference for personalized medicine. There are three key challenges that persist to occur in the development of these biologic drugs: establishing product similarity, product toxicity, and global accessibility. These can be overcome by techniques that facilitate the isolation and interrogation of single cells in biotechnology companies. Factors such as high prevalence of cancer and infectious diseases, increasing healthcare expenditure, and growth in the Asian biotechnology companies drive the growth of this market.
The report provides analysis of the below-mentioned end users:
Human cells are the largest category, and they will also witness the highest CAGR during the forecast period. This is due to the increasing investment in stem cell research, and increasing prevalence of infectious diseases among the geriatric population. Human cells help in understanding the molecular and genetic basis of cancer, and various other infectious diseases. Various research studies are carried out on human cell for the purpose of diagnosing diseases at a better level. Stems cells have been extensively used for research purpose and for providing new treatment therapies.
The following cell types were studied:
Drive strategic growth with comprehensive market analysis
North America has the leading position in the single-cell analysis market, and it will hold the same position till 2032, with a value of around USD 4 billion.
This is attributed to the rapid adoption of advanced analytical tools, robust healthcare system, various government funding programs, and the existence of a large pool of trained professionals. The surging demand for personalized medicine and rising prevalence of infectious diseases are the other key factors propelling the industry growth in this region. The existence of various key players and the increasing R&D expenditure are also credited for this.
In North America, the U.S. holds the leading position, attributed to the favorable reimbursement policies for healthcare services. Approximately 1,000 different single-cell RNA analysis tools are in wide usage across the U.S. The availability of such a wide diversity of tools makes the healthcare system of the country strong and, hence, contributes toward the market growth.
According to government statistics, around 350 deaths each day are caused by lung cancer, which is 2.5 times more than most other types. The increasing incidence of this disease in the U.S. has led to a rise in the demand for single cell analyses. Additionally, the whole-genome next-generation sequencing technology is being used for this purpose in the U.S. and Canada as it offers quicker and more-accurate results.
Moreover, as per government reports, the prevalence of cancer among American Indians and Alaskan natives is about 1,000 cases per 10,000, but this is 64% lower than in Whites. Cigarette smoking is the second-largest risk factor for cancer in the U.S. Smoking prevalence is higher among American and Alaskan women than men, and about a quarter of the people suffering from cancer are regular cigarette smokers.
The Asia-Pacific region is expected to showcase the fastest growth, with 13% CAGR. This will be because a large number of people here are suffering from infectious diseases, which is propelling the requirement for diagnosis. Moreover, governments organize various campaigns to create awareness about infectious diseases and advanced tools for diagnosing them at an early stage, which has driven the growth in the volume of such medical analyses in the region.
In the APAC region, governments have initiated various funding programs to create awareness about single-cell analysis. In developing nations, such as India and China, the demand for precision medicine is increasing significantly as well.
Furthermore, the market is propelled by the increasing demand for isolation products, rising geriatric population, and surging investments in the R&D sector. Moreover, the National Cancer Registry program in India estimates that 1 in 9 Indians will develop cancer in their life and approximately 1 in 68 males will have lung cancer and 1 in 29 females will have breast cancer.
The following regions and countries were studied:
The market is consolidated as single-cell analysis tools take a lot of capital investment and high technical skills to develop. Additionally, the systems must undergo rigorous trials before the FDA, EMA, and other prominent regulatory agencies approve them. This is why only well-established life sciences and biotechnology companies hold significant shares. Moreover, end users major comprise large hospitals, well-funded diagnostic laboratories, established pharmaceutical & biopharmaceuticals, and prominent academic & research institutes working on government grants. These entities usually have long-term supply & service contracts with the major players, which limits the scope for newcomers.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages